



Scientific Program

Friday, May 27th 2022

8:15 – 08:30 Congress Opening

8:30 – 10:45 Plenary Session 1: Emerging trends in cancer associated thrombosis

Chairs: Per Morten Sandset (Norway), Rita Selby (Canada)

PL01: Frits Mulder (The Netherlands). VTE in cancer in contemporary era

PL02: Cliona Kirwan (UK). Contemporary breast cancer treatment-associated thrombosis

PL03: Grigoris Gerotziafas (France). Machine learning for risk stratification of CAT

PL04: Kristen M. Sanfilippo (USA). Venous Thromboembolism and Risk Stratification in Hematological Malignancies

Oral Communications

OC-01: Mortality impact of cancer-associated venous thromboembolism: Final analysis from Oncothromb12-01 study

M. Ruiz, A. Muñoz, C. Font, V. Castellón, M. Salgado, E. Martínez, A. Rupérez, A. Cárdenas, R. Martín-Lozano, I. González-Caraballo, R. Jiménez, L. Ortega, E. Salas, J.M Soria (Spain)

OC-02: Outcomes of cancer-associated isolated superficial vein thrombosis in daily practice

F. Langer, H.E. Gerlach, A. Schimke, A. Heinken, U. Hoffmann, T. Noppeney, D. Pittrow, J. Klotsche, E. Rabe, R. Bauersachs (Germany)

10:45-11:15 Coffee Break



11:15 – 13:30 Plenary Session 2: Exploring the relationship between hemostasis and cancer: New insights

Chairs: Anne-Karin Olsson (Sweden), Raffaella Giavazzi (Italy)

PL05: Ronit Satchi-Fainaro (Israel). P-Selectin as an emerging target for cancer therapy

PL06: Simon Mantha (USA). Cancer Genetic Alterations and Risk of Venous Thromboembolism

PL07: Axel Rosell (Sweden). The role of neutrophil extracellular traps in cancer-associated thrombosis

PL08: Nina Iversen (Norway). Role and regulation of TFPI and FV in tumor cells

Oral Communications

OC-03: Platelet-derived von Willebrand factor is involved in thrombosis and metastatic growth of melanoma in the brain

S.W. Schneider, J.R. Robador, F. T. Mayer, M. Feinauer, L. Keller, K. Pantel, J. Stadler, C. Gorzelanny, F. Winkler, and A.T. Bauer (Germany)

OC-04: Neutrophil extracellular traps promote cancer-associated inflammation and myocardial stress

J. Cedervall, M. Herre, A. Dragomir, F. Rabelo-Melo, A. Svensson, C. Thålin, A. Rosell, V. Hjalmar, H. Wallén, H. Lindman, G. Pejler, E. Hagström, M. Hultström, A. Larsson, A.K. Olsson (Sweden)

13:30 – 14:30 Lunch Special Lecture

Chairs: Anna Falanga (Italy)

Maria Luisa Lavitrano (Italy). Importance of biobanking in cancer and thrombosis research: building new 'horizons'

14:30 – 15:00 Coffee and pastries

15:00 – 17:30 Plenary Session 3: Role of hemostatic biomarkers in CAT and cancer progression

Chairs: Cihan Ay (Austria), Barry Kevane (Ireland)

PL09: Jamie Marie O'Sullivan (Ireland). Bi-directional cross talk between coagulation and cancers: current assessment of pre-clinical evidence

PL10: Aurélien Delluc (Canada). PET scan for occult cancer among patients with unprovoked VTE: what do we know?

PL11: Laurence Panicot-Dubois (France). The relationship between platelets and cancer cells in the growing thrombus and in the development of cancer



PL12: Marina Marchetti (Italy). Hemostatic system activation in breast cancer: searching for new biomarkers of cancer outcome

Oral Communications

OC-05: Thromboembolism after Incident Colorectal Cancer in the Netherlands: Incidence, Predictors, and Prognosis

R.J.S. Anijs, Q. Chen, W.M. Lijfering, S.C. Cannegieter (The Netherlands)

OC-06: Identification of predictive hemostatic biomarkers for cancer diagnosis: results from the HYPERCAN study

S. Gamba, M. Marchetti, L. Russo, C. Giaccherini, S. Bolognini, C. J. Tartari, C. Verzeroli, C. Ticozzi, A. Vignoli, F. Schieppati, G. Sampietro, P. Malighetti, D. Spinelli, and A. Falanga (Italy)

OC-07: Contact pathway activation and risk of venous thromboembolism in patients with pancreatic cancer: the prospective SENECA study

F.T.M. Bosch, E. Campello, M.W. Henderson, F.I. Mulder, S. Gavasso, C. Bassi, J.W. Wilmink, H.M. Otten, N. van Es, A. Ilich, N. Key, H.R. Büller, P. Simioni (The Netherlands, USA, Italy)

17:30 - 18:00 Coffee Break

18:00 – 19:00 **DEBATE: Catheter-associated Thrombosis in cancer patients: To prophylax or not to prophylax?**

Chairs: **Luis Jara-Palomares (Spain), Elena Faioni (Italy)**

YES: Marc Carrier (Canada)

NO: Mario Mandalà (Italy)

19.00 – 20.00 **Plenary Lecture: 7th Simon Karparkin Memorial Lecture**

The Conference Chairs

Introduction to Lecture: Alok A Khorana (USA)

Joe Palumbo (USA). Crosstalk between hemostasis and immunity in cancer pathogenesis



Saturday, May 28th 2022

8:30 – 10:45 Plenary session 4: Hemostatic complications and novel anti-cancer therapies

Chairs: Ilene Weitz (USA), Wolfram Ruf (Germany)

PL13: Keith McCrae (USA). Old is new again: emergence of thromboembolic complications in cancer patients on immunotherapy

PL14: Florian Moik (Austria). Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer treatments

PL15: Tzu-Fei Wang (Canada). Drug-drug interactions: Implications for anticoagulation use in patients with cancer

PL16: Rupert Bauersachs (Germany). Bleeding risk with direct oral anticoagulants in cancer patients

Oral Communications

OC-08: The Khorana score and risk of venous thromboembolism in patients with cancer treated with immune checkpoint inhibitors

T.F. Overvad, A.G. Ording, P.B. Nielsen, G. Piazza, S. Noble⁵, T.B. Larsen, F. Skjøth (UK)

OC-09: Rivaroxaban compared to no treatment in early breast cancer patients (the TIP Trial): initial findings for a phase II preoperative window-of-opportunity randomized controlled trial

C.C. Kirwan, J. Castle, S.A. Pritchard, N.J. Bundred, J Thachill, J.R. Harvey, P.G. Roy, A. Volleamere, E. Blower, C. Palmieri, B. Hogan, R. Vinayagam, K. Cox, A. Marshall, L. Turner, G. Gibson, H. Scott, C. Holcombe (UK)

10:45 – 11:15 Coffee break

11:15 – 13:30 Plenary Session 5: COVID-19, thrombosis, and cancer

Chairs: Valerio De Stefano (Italy), Howard A. Liebman (USA)

PL17: Nicole Kuderer (USA). Cancer and COVID-19: where are the data?

PL18: Marcel Levi (UK). COVID-19 associated coagulopathy and thrombosis in cancer

PL19: Mandy N Lauw (The Netherlands). COVID-19 impact on thrombosis in hematological malignancies



PL20: Jean M. Connors (USA). Vaccine-induced immune thrombotic thrombocytopenia and patients with cancer

Oral Communications

OC-10: Plasmatic von Willebrand factor encapsulates blood circulating melanoma cells to prevent their hematogenous metastasis

Y. Wang, X. Liu, T. Obser, A.T. Bauer, M. Kusche-Gullberg, S. W. Schneider, C. Gorzelanny (Norway)

OC-11: Safety and Efficacy of Apixaban as Thromboprophylaxis in Multiple Myeloma Patients Receiving Chemotherapy: a Prospective Cohort Study

Z. Sayar, C. Gates, S. Bristogiannis, A. Patel, M.O. Ogunbiyi, A. Tailor, K. Yong, M. Thomas (UK)

13:30 – 14:30 Lunch sessions

14:30 – 15:00 Coffee and pastries

15:00 – 17:00 **Poster Sessions**

Poster Session 1: Biomarkers/Hypercoagulability I

Chair: E. Castoldi (the Netherlands)

Poster Session 2: Bleeding complications

Chair: E. De Candia (Italy)

Poster Session 3: Epidemiology

Chair: M. Panova-Noeva (Germany)

Poster Session 4: Hemostatic proteins and cancer biology

Chair: G. Taraboletti (Italy)

Poster Session 5: Therapeutic challenges

Chair: M. Napolitano (Italy)

Poster Session 6: Thromboprophylaxis and thrombotic risk assessment

Chair: F. Schieppati (Italy)

Poster Session 7: Biomarkers/Hypercoagulability II

Chair: N. Maugeri (Italy)



Poster Session 8: Treatment of thrombosis in cancer

Chair: E. Rossi (Italy)

17:00 – 18:30 ROUNDTABLE: Multidisciplinary approach in Cardiovascular Oncology

Chairs: Arina ten Cate-Hoek (The Netherlands), Ingrid Pabinger (Austria)

Introduction: A. Khorana (USA). Building a CAT Clinic - Real-World Systems Approaches to Prevention and Treatment

Discussants: B. Brenner (Israel), AJ Kakkar (UK), N. van Es (The Netherlands), I. Elalamy (France), A.J. Munoz (Spain), M.B. Monreal (Spain)



Sunday, May 29th 2022

8:30 – 10:45 Plenary Session 6: Cardiovascular complications in cancer patients

Chairs: Pantep Angchaisuksiri (Thailand), Bianca Rocca (Italy)

PL21: Hugo Ten Cate (The Netherlands): Evolving data on cardiovascular complications in cancer

PL22: Alexandros D. Tselepis (Greece): Cardiotoxic effects of antitumor agents: Pathogenetic mechanisms

PL23: Antonella Tufano (Italy): Optimizing antithrombotic therapy for atrial fibrillation in cancer

PL24: Josè J Fuster (Spain): Clonal hematopoiesis and cardiovascular complications in cancer patients and survivors

Oral Communications

OC-12: Stroke and Risk of Cancer: A Danish Population-based Cohort Study

N. Skajaa, K. Veres, F.S. Troelsen, J.D. Petersen, K. Adelborg, H.T. Sørensen (Denmark)

OC-13: Differentially expressed coagulome genes (DECGs) are prognostic in breast cancer

M. Tinholt, X. Tekpli, V. Kristensen, P.M. Sandset, N. Iversen (Norway)

10:45 – 11:45 Debate: Duration of VTE treatment beyond 6 months: To continue or not to continue?

Chairs: Alexander Cohen (UK), Suzanne C. Cannegieter (NL)

YES: Agnes Lee (Canada)

NO: Marcello Di Nisio (Italy)

11:45 - 12:45 *Brunch*

12:45 – 15:30 Plenary 7: Prevention and treatment of Cancer-Associated Thromboembolism

Chairs: Roberto Labianca (Italy), Annie Young (UK)

PL25: Anna Falanga (Italy): Prevent and Treat VTE in cancer patients: ESMO Guidelines

PL26: Jeffrey Zwicker (USA): The impact of warfarin on overall survival in cancer patients with VTE

PL27: Michails Karamouzis (Greece): The impact of thromboprophylaxis on the survival of patients with pancreatic cancer

PL28: Avi Leader (Israel): Cancer-Associated Non-Bacterial Thrombotic Endocarditis



PL29: Simon Noble (UK). Risk benefit analysis of anticoagulation in elderly cancer patients

Oral Communications

OC-14: Effectiveness and safety of 6-months' treatment with different full-dose enoxaparin regimens in patients with cancer-associated venous thromboembolism: a subgroup analysis of the RIETECAT cohort study

M. Monreal, L. Bertoletti, J. J. López-Núñez, G. Tiberio, S. Soler, C. Gómez-Cuervo, Á. Fidalgo, M. Mellado, P. López-Miguel, J. A. Díaz-Peromingo, and the RIETE Investigators (France, Spain)

OC-15: Targeted thromboprophylaxis in ambulatory patients receiving anticancer therapies for lung or gastrointestinal cancers (TARGET-TP); a randomized trial

M. Alexander, S.J. Harris, C. Underhill, J.T. orres, S.Sharma, N. Lee, H. Wong, R. Eek, M. Michael, J. Tie, J. Rogers, A. Heriot, D. Ball, M. MacManus, R. Wolfe, B. Solomon, K. Burbury (Australia)

OC-16: Comparison of VTE recurrence, bleeding-related hospitalization and all-cause mortality in patients with active cancer in two patient populations, based upon cancer types considered to have high and low risks of bleeding, receiving DOACs or LMWH – The OSCAR UK Study

A.T. Cohen, C. Wallenhorst, C. Ay, B. Schaefer, K. Abdelgawwad, G. Psaroudakis, G. Brobert, C. I. Coleman, A. Ekbom, A.Y.Y. Lee, A. Khorana, C. Becattini, M. Carrier, M. Rivera, C. Martinez (UK, Germany, USA, Sweden, Canada)

15:30 Concluding Remarks: Anna Falanga (Italy)